<div class="headers"><div>Fig. 2 Change from baseline in E-RS scores and proportion of E-RS responders at Week 24, overall and by GOLD group a and b RS-Total score; c and d RS-Breathlessness domain; e and fRS-Cough & Sputum domain; g and h RS-Chest Symptoms domain. *p < 0.05, **p < 0.01, ***p < 0.001 vs placebo. Change from baseline data are LS means (SE). Responder data are OR (95 % CI). aplacebo n = 578; aclidinium n = 583; bplacebo n = 72; aclidinium n = 64; cplacebo n = 506; aclidinium n = 519. BID, twice daily; CI, confidence interval; E-RS, Evaluating Respiratory Symptoms; GOLD, Global initiative for chronic Obstructive Lung Disease; LS, least squares; OR, odds ratio; SE, standard error</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">Fig. 2 Change from baseline in E-RS scores and proportion of E-RS responders at Week 24, overall and by GOLD group a and b RS-Total score; c and d RS-Breathlessness domain; e and f</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">RS-Cough & Sputum domain; g and h RS-Chest Symptoms domain. *p < 0.05, **p < 0.01, ***p < 0.001 vs placebo. Change from baseline data are LS means (SE). Responder data are OR (95 % CI). aplacebo n = 578; aclidinium n = 583; bplacebo n = 72; aclidinium n = 64; cplacebo n = 506; aclidinium n = 519. BID, twice daily; CI, confidence interval; E-RS, Evaluating Respiratory Symptoms; GOLD, Global initiative for chronic Obstructive Lung Disease; LS, least squares; OR, odds ratio; SE, standard error</p></td>
</tr>
</tbody>
</table>
